Objective: The C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR) are common markers of inflammation in patients with rheumatoid arthritis (RA). The serum amyloid A (SAA) level is also a sensitive inflammatory marker, and biologic agents (BA) including tocilizumab (TCZ), an inhibitor of interleukin-6 (IL-6), have been reported to decrease the SAA level. However, to date, few reports have compared the SAA levels, disease activity, other inflammatory markers and prospective outcomes following treatment with BA. The aim of this study was to assess the disease activity and levels of SAA and other inflammatory markers in patients with RA receiving such agents.
Methods: The subjects included 32 patients with RA who were commenced on biologic treatment during or after July 2008 (17 patients received tumor necrosis factor (TNF) inhibitors and 15 patients received TCZ). The swollen joint count, tender joint count, Disease Activity Score (DAS) 28-ESR score and levels of SAA, ESR, CRP and matrix metalloproteinase-3 were assessed before treatment and at two, four and six months after treatment, respectively.
Results: No significant differences were found between the groups at baseline. At two, four and six months after treatment, the SAA, ESR and CRP levels in the TCZ group were significantly lower than those in the TNF inhibitor group, respectively. The DAS28-ESR scores obtained six months after treatment was significantly correlated with the SAA, ESR and CRP levels obtained two and four months after treatment in the TNF inhibitor group and with the SAA levels obtained two and four months after treatment in the TCZ group.
Conclusions: The DAS28-ESR score was used as an endpoint in this study. Comparatively high values have been reported for both efficacy and remission rates, particularly in patients treated with TCZ, which directly inhibits the inflammatory response. Furthermore, there are reports of relationships between the DAS28-ESR score and clinical disease activity index and simplified activity disease index values, thus indicating that DAS28 assessments are sufficiently useful. In this study, the DAS28-ESR scores obtained at six months after treatment significantly correlated with the SAA levels obtained after two and four months, but only in the TCZ group. These results suggest that it may be possible to use the SAA level as a predictive factor for the therapeutic effects of TNF inhibitor and/or TCZ therapy in patients with RA.
抄録全体を表示